Rating Change
B of A Securities analysts reiterated a Underperform rating on Moderna, Inc. (NASDAQ:MRNA) on July 07, 2026.
Rating Change B of A Securities analysts reiterated a Underperform rating on Moderna, Inc. (NASDAQ:MRNA) on July 07, 2026. Market Context Moderna, Inc.

B of A Securities analysts reiterated a Underperform rating on Moderna, Inc. (NASDAQ:MRNA) on July 07, 2026.
Moderna, Inc. operates in the Healthcare sector. The stock currently trades at $79.09 with a market capitalization of $11.6B. The stock has gained 247.2% over the past 52 weeks.
Analyst coverage from B of A Securities provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Moderna, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Among the 10 most recent ratings: 2 Buy, 6 Hold, 2 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 07, 2026 | B of A Securities | Underperform | N/A |
| Jun 26, 2026 | Piper Sandler | Overweight | N/A |
| Jun 08, 2026 | B of A Securities | Underperform | N/A |
| May 04, 2026 | UBS | Neutral | N/A |
| May 04, 2026 | RBC Capital | Sector Perform | N/A |
Related Tools: Analyst Ratings Dashboard | View MRNA Stock Page
A Underperform rating from B of A Securities reflects the analyst's outlook on Moderna, Inc. (NASDAQ:MRNA). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the MRNA forecast page.
Current market data
NASDAQ · MRNA
$145.55
Down: -$3.32 · -2.23%
Live quote updated
Keep reading